August 2022

Moving Towards Biosimilar Drugs

2022-11-17T13:38:05-05:00August 4th, 2022|Articles|

Written by Vanessa Yoon Calvelo, PhD August 3, 2022 Contents What are Biosimilar Drugs? Why are Biosimilars Being Developed? Biosimilars are not the Equivalent of Generics Biosimilar Development Biosimilar Monoclonal Antibodies De Novo Protein Sequencing Solutions in Biosimilar Development What are Biosimilar Drugs? Biosimilar drugs, also known [...]

December 2021

Next Generation Protein Sequencing in Veterinary Medicine and Industry

2022-07-05T14:24:01-04:00December 3rd, 2021|Whitepapers|

Since 2006, the One Health Initiative (OHI)’s goal has been to demonstrate the inextricable link between humans, animals, and the environment. Certainly, the current global pandemic is a great testament to the ties between climate change, humans, and animals that OHI has been working to highlight. The rise of other zoonotic diseases (e.g., Hendra, and Nipah viruses) not only directly affect humans through disease transmission but may also result in deep impacts to the food supply

October 2021

Ushering the New Era in Anti-Drug Antibody Assays with Next Generation Protein Sequencing

2022-04-18T20:15:18-04:00October 15th, 2021|Whitepapers|

Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.

July 2021